Anti-DDR1 antibody having anti-tumor activity

Patent metadata

Field	Value
Publication number	US-9550835-B2
Application number	US-201214240057-A
Country	US
Kind code	B2
Filing date	Aug 23, 2012
Priority date	Aug 23, 2011
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-β in cells.

First claim

The invention claimed is:

1. An antibody that binds to the stalk domain of Discoidin Domain Receptor 1 (DDR1) (SEQ ID NO:4) and not to the discoidin domain of DDR1 (SEQ ID NO:3).

2. The antibody according to claim 1 that is a chimeric antibody or humanized antibody.

3. The antibody according to claim 1 that is a minibody.

4. The antibody according to claim 1 that is linked with a cytotoxic agent.

5. A monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

6. A humanized antibody, wherein the antibody is a humanized version of a monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

7. An antibody that binds to the stalk domain of DDR1 (SEQ ID NO:4), wherein the antibody comprises six CDRs identical to heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3, respectively, of a monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

8. The antibody of claim 1 , wherein the antibody has the same epitope specificity as a monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

9. An antibody that binds to the stalk domain of DDR1 (SEQ ID NO:4) and is produced by a host cell expressing cDNAs encoding antibody heavy and light chains identical to heavy and light chains of a monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

10. An antibody that binds to the stalk domain of DDR1 (SEQ ID NO: 4), said antibody comprising light and heavy chain variable domain amino acid sequences identical to those of a monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

11. An antibody that binds to the stalk domain of DDR1 (SEQ ID NO: 4), said antibody comprising light and heavy chains identical to the light and heavy chains of a monoclonal antibody produced by a hybridoma deposited under any one of Accession Nos. FERM BP-11399, FERM BP-11398, and FERM BP-11397.

Assignees

• Ono Mei
• Sano Yuji
• Suzuki Tsukasa
• Chugai Pharmaceutical Co Ltd

Inventors

• Ono Mei
• Sano Yuji
• Suzuki Tsukasa

Classifications

• C07K16/40 Primary

  against enzymes · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K16/3023

  Lung · CPC title

• C07K16/2851 Primary

  against the lectin superfamily, e.g. CD23, CD72 · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title